Potential link between heart inflammation and mRNA COVID shots found by EU

European Union (EU) drug regulator has found a possible link between very rare heart inflammation and COVID-19 vaccines from Pfizer-BioNTech and Moderna, as reported on Friday, while reassuring that the benefits of these vaccines outweighed any risks.


The safety committee of European Medicines Agency (EMA) advised listing the conditions, myocarditis and pericarditis, to be listed as side-effects of the two mRNA vaccines.


EMA in total reviewed more than 300 cases of myocarditis and pericarditis in the European Union, Iceland, Norway and Liechtenstein.


EMA also added that such cases primarily occurred within 14 days of inoculation and more often after the second dose and in younger adult men.


The US had similar findings regards to these vaccines. 


Symptoms from the conditions include breathlessness, palpitations and chest pain.

EMA’s safety panel also advised that people with a history of the rare blood disorder capillary leak syndrome (CLS), must not be vaccinated with Johnson & Johnson’s shot.


EMA is continuously monitoring the safety of approved vaccines as they are rolled out more widely.